Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells. Local targets link to admitted publications; unresolved targets remain external evidence.
The PARP Way to Epigenetic Changes
10.3390/genes12030446 · 2021 · External reference
Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics
10.3389/fcell.2021.801200 · 2021 · External reference
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
10.1016/j.molcel.2015.01.034 · 2015 · External reference
Poly(adenosine diphosphate ribose)
10.1016/s0079-6603(08)60102-6 · 1973 · External reference
PolyADP-ribosylation and cancer
10.1111/j.1349-7006.2007.00567.x · 2007 · External reference
Purification and properties of glycohydrolase from calf thymus splitting ribose-ribose linkages of poly(adenosine diphosphate ribose)
10.1016/s0021-9258(19)42597-0 · 1974 · External reference
Mode of action of poly(ADP-ribose) glycohydrolase
10.1016/0167-4781(94)90058-2 · 1994 · External reference
ADP-ribosylhydrolase 3 (ARH3), not poly(ADP-ribose) glycohydrolase (PARG) isoforms, is responsible for degradation of mitochondrial matrix-associated poly(ADP-ribose)
10.1074/jbc.m112.349183 · 2012 · External reference
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
10.1056/nejmoa1706450 · 2017 · External reference
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
10.1016/j.ejca.2023.01.031 · 2023 · External reference
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
10.1056/nejmoa1810858 · 2018 · External reference
PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
2022 · External reference
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
10.3389/fcell.2020.564601 · 2020 · External reference
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
10.14740/wjon1166 · 2019 · External reference
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
10.1056/nejmoa1903387 · 2019 · External reference
PARP inhibitor resistance: the underlying mechanisms and clinical implications
10.1186/s12943-020-01227-0 · 2020 · External reference
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks
10.1016/j.cell.2010.03.012 · 2010 · External reference
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
10.1016/j.tcb.2019.07.008 · 2019 · External reference
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
10.1073/pnas.0806092105 · 2008 · External reference
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
10.1038/s41467-018-03917-2 · 2018 · External reference
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
10.1016/j.ccell.2018.05.008 · 2018 · External reference
Replication fork stability confers chemoresistance in BRCA-deficient cells
10.1038/nature18325 · 2016 · External reference
Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells
10.1158/0008-5472.can-18-1037 · 2019 · External reference
Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents
10.1016/0027-5107(90)90173-2 · 1990 · External reference
Specificity of mutations induced by methyl methanesulfonate in mismatch repair-deficient human cancer cell lines
10.1016/s0027-5107(99)00091-3 · 1999 · External reference
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
10.1158/2159-8290.cd-18-0715 · 2019 · External reference
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
10.1002/path.4140 · 2013 · External reference
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
10.1158/0008-5472.can-12-2753 · 2012 · External reference
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance
10.1158/0008-5472.can-14-0839 · 2015 · External reference
NAD(+) metabolism, stemness, the immune response, and cancer
10.1038/s41392-020-00354-w · 2021 · External reference
PARP inhibitors: Synthetic lethality in the clinic
10.1126/science.aam7344 · 2017 · External reference
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis
10.18632/oncotarget.20577 · 2017 · External reference
NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP
10.1158/1078-0432.ccr-17-2575 · 2018 · External reference
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
10.3390/cancers12123855 · 2020 · External reference
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
10.1186/s13045-022-01384-3 · 2022 · External reference
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
10.1002/emmm.201201250 · 2012 · External reference
The Redox Status of Cancer Cells Supports Mechanisms behind the Warburg Effect
10.3390/metabo6040033 · 2016 · External reference
Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1
10.1080/15384047.2019.1591675 · 2019 · External reference
Review of various NAMPT inhibitors for the treatment of cancer
10.3389/fphar.2022.970553 · 2022 · External reference
